Search

Displaying results 4721 - 4730 of 7283 in total
  1. Drug

    AZD-2836

    go.drugbank.com/drugs/DB06031
    Investigational

    AZD-2836 is an inhibitor of the nonstructural protein 5A (NS5A).[A264853] The drug is being investigated for treatment of hepatitis C because AZD-2836 has in vitro anti-HCV activity.[A264858]

  2. Drug

    Fenproporex

    go.drugbank.com/drugs/DB01550
    ApprovedIllicitWithdrawn

    It is used as an appetite suppressant and a treatment for obesity. … effects are less notorious than with some other agents such as diethylpropion and mazindol. [7] In the United States fenproporex was never approved by the FDA for clinical use due to a lack of efficacy

    Products: IFA-DIETY A. P.
  3. Drug

    Satralizumab

    go.drugbank.com/drugs/DB15762
    ApprovedInvestigational

    [A218551] It received subsequent approvals in Switzerland and Japan,[A218551] and was approved for use by the FDA in August 2020,[L15566] becoming the 3rd treatment to receive FDA approval for NMOSD (after … Satralizumab is a recombinant humanized monoclonal antibody targeted against human interleukin-6 (IL-6) receptors, similar to [tocilizumab], which is produced in Chinese hamster ovary cells and based on

  4. Drug

    Londamocitinib

    go.drugbank.com/drugs/DB19190
    Investigational

    Londamocitinib is under investigation in clinical trial NCT06020014 (Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients With Moderate-to-severe Asthma Uncontrolled on Medium-high

  5. Drug

    Apadamtase alfa

    go.drugbank.com/drugs/DB15164
    ApprovedInvestigational

    [A262076] Patients with cTTP have a severe deficiency of a plasma metalloproteinase called ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13), which is responsible … Thrombotic thrombocytopenic purpura (TTP) is a rare blood clotting disorder characterized by thrombocytopenia, microangiopathic hemolytic anemia, and various degrees of organ damage.

  6. Drug

    Nirogacestat

    go.drugbank.com/drugs/DB12005
    ApprovedInvestigational

    Nirogacestat is a small-molecule gamma-secretase inhibitor that was investigated as a potential treatment for desmoid tumors. … confirmed objective response rate was observed to be 41% compared to 8% with the placebo.

  7. Drug

    Omaveloxolone

    go.drugbank.com/drugs/DB12513
    ApprovedInvestigational

    Omaveloxolone (RTA-408) is a semisynthetic oleanane triterpenoid with antioxidant and anti-inflammatory properties. … Therefore, the use of Nrf2 activators such as omaveloxolone represents a therapeutic advantage in this group of patients.

  8. Drug

    Pafolacianine

    go.drugbank.com/drugs/DB15413
    ApprovedInvestigational

    Pafolacianine, or OTL38, is a folate analogue conjugated with a fluorescent dye that absorbs light in the near-infrared (NIR) spectrum [A242572] within a range of 760 nm to 785 nm, with a peak absorption … It emits fluorescence within a range of 790 nm to 815 nm with a peak emission of 796 nm.

    Categories: Compounds used in a research, industrial, or household setting
  9. Drug

    Lorcaserin

    go.drugbank.com/drugs/DB04871
    ApprovedInvestigationalWithdrawn

    This decision was based on the results of a clinical trial assessing the risk of heart-related problems that found that patients treated with lorcaserin may have a higher risk of cancer. … In February 2020, the FDA issued a Drug Safety Communication requesting the manufacturer of Belviq (lorcaserin hydrochloride tablets, 10 mg) and Belviq XR (lorcaserin hydrochloride extended-release tablets

  10. Drug

    QXL138AM

    go.drugbank.com/drugs/DB18552
    Investigational

    QXL138AM is a masked immunocytokine (MIC) comprised of an anti-CD138 immunoglobulin G1 antibody fused to interferon alpha 2a. It binds the CD138 protein on the surface of the tumour cells.

    Synonyms: Masked immunocytokine (MIC) comprised of an anti-CD138 immunoglobulin G1 antibody fused to interferon alpha 2a